Scholarlink

Background <p>Results from blood pressure (BP) control interventional trials can inform clinicians and health systems pursuing better BP control, but they must be interpreted cautiously.</p> Objective <p>Deconstruct the observed drop in systolic BP (SBP) into components attributable to increased adherence to previously prescribed medications, regression to the mean, and initiation of new medications.</p> Design <p>Secondary analysis of BP Home, a pragmatic randomized controlled trial.</p> Participants <p>Patients owning a smartphone who reported uncontrolled BP at their last clinic visit (&gt; 145&#xa0;mmHg) and a desire to lower their BP by &gt; 10&#xa0;mmHg.</p> Interventions <p>In BP Home, participants were randomly assigned to receive one of two devices for self-measurement of BP and followed for up to 24&#xa0;months via electronic health records (EHR).</p> Approach <p>The primary outcome was EHR-recorded office SBP. We fit SBP trajectories for each participant using linear mixed models, and estimated the contributions of medication adjustments, and increased adherence to pre-existing BP medications due to their enrollment in a research study (i.e., a Hawthorne effect). Regression to the mean was calculated for each participant as the difference between their last measured pre-enrollment SBP and their modeled SBP trajectory at enrollment.</p> Key Results <p>Among participants taking BP medications at enrollment, we estimated an average immediate drop in SBP of −4.2&#xa0;mmHg (95% CI, −5.1 to −3.3; <i>p</i> &lt; 0.001) at enrollment, explainable by increased medication adherence following study enrollment. Starting a new medication class post-enrollment resulted in an SBP drop of −4.1&#xa0;mmHg (95% CI, −5.3 to −2.8; <i>p</i> &lt; 0.001). The average expected regression to the mean was −3.9 (95% CI, −4.4 to −3.3; <i>p</i> &lt; 0.001).</p> Conclusions <p>A significant portion of BP reductions in trials may stem from increased adherence to pre-existing medications arising from enrollment in a research study and enhanced awareness of their elevated BP.</p> NIH Trial Registry Number <p>NCT03796689 (registered on 2019-01-04)</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Estimating the Hawthorne Effect in Real-World Blood Pressure Control Trials: An Analysis of the BP Home Trial

  • 期刊论文

  • 发表日期：

    2026年3月12日

查看全文
  • Max Rosen,
  • Valy Fontil,
  • Madelaine Faulkner Modrow,
  • Steven M. Smith,
  • Thomas W. Carton,
  • Alanna M. Chamberlain,
  • Emily C. O’Brien,
  • Soo Park,
  • Jaime Orozco,
  • Rhonda M. Cooper DeHoff,
  • Gregory Wozniak,
  • Michael Rakotz,
  • Charles E. McCulloch,
  • Mark J. Pletcher

摘要

Background

Results from blood pressure (BP) control interventional trials can inform clinicians and health systems pursuing better BP control, but they must be interpreted cautiously.

Objective

Deconstruct the observed drop in systolic BP (SBP) into components attributable to increased adherence to previously prescribed medications, regression to the mean, and initiation of new medications.

Design

Secondary analysis of BP Home, a pragmatic randomized controlled trial.

Participants

Patients owning a smartphone who reported uncontrolled BP at their last clinic visit (> 145 mmHg) and a desire to lower their BP by > 10 mmHg.

Interventions

In BP Home, participants were randomly assigned to receive one of two devices for self-measurement of BP and followed for up to 24 months via electronic health records (EHR).

Approach

The primary outcome was EHR-recorded office SBP. We fit SBP trajectories for each participant using linear mixed models, and estimated the contributions of medication adjustments, and increased adherence to pre-existing BP medications due to their enrollment in a research study (i.e., a Hawthorne effect). Regression to the mean was calculated for each participant as the difference between their last measured pre-enrollment SBP and their modeled SBP trajectory at enrollment.

Key Results

Among participants taking BP medications at enrollment, we estimated an average immediate drop in SBP of −4.2 mmHg (95% CI, −5.1 to −3.3; p < 0.001) at enrollment, explainable by increased medication adherence following study enrollment. Starting a new medication class post-enrollment resulted in an SBP drop of −4.1 mmHg (95% CI, −5.3 to −2.8; p < 0.001). The average expected regression to the mean was −3.9 (95% CI, −4.4 to −3.3; p < 0.001).

Conclusions

A significant portion of BP reductions in trials may stem from increased adherence to pre-existing medications arising from enrollment in a research study and enhanced awareness of their elevated BP.

NIH Trial Registry Number

NCT03796689 (registered on 2019-01-04)

Graphical Abstract